Previous 10 | Next 10 |
VANCOUVER, Washington, Nov. 03, 2021 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a late-stage biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications, announced today updated results from its...
Activist Group Failed to Submit its Proxies Without Activist Group’s Proxies, Annual Meeting Lacked Quorum CytoDyn Inc. (OTCQB: CYDY) (the “Company”), a late-stage biotechnology company developing leronlimab, a CCR5 antagonist with the potential ...
Management expects the non-clinical and CMC sections of the BLA to be resubmitted to FDA in November VANCOUVER, Washington, Oct. 27, 2021 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a late-stage biotechnology company developing leronlimab, a CC...
MIAMI, Oct. 26, 2021 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal with an extensive history of providing unparalleled content for the Emerging Growth Companies and Markets announces the Schedule of the 19 th Emerging Growth Conference. The Em...
Based on previous strong sub-population analysis in CD12 trial, CytoDyn intends to file for an EUA when interim analysis of 127 patients is completed VANCOUVER, Washington, Oct. 25, 2021 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a late-stage ...
VANCOUVER, Washington, Oct. 21, 2021 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a late-stage biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications, announced today Nader Pourhassan, Ph.D.,...
2021 Annual Meeting Will be Held as Scheduled on October 28, 2021 CytoDyn Urges Shareholders to Vote on Company’s BLUE Proxy Card to Ensure their Vote Counts All Proxies and Votes in Favor of the Activist Group’s Nominees Will be Disregarded Cyt...
Urges Shareholders to Ensure that Their Vote Counts Proxies and Votes in Favor of the Activist Group’s Nominees Will be Disregarded Shareholders Will Receive Company Proxy Material this Week CytoDyn Inc. (OTCQB: CYDY) (“CytoDyn” or the ...
A group of long-time stockholders (the “Investor Group”) of CytoDyn Inc. (“CYDY” or the “Company”) that has nominated five highly experienced director candidates to serve on the Company’s Board of Directors today commented on the decision...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Plowing through the most populated regions of the world like a hurricane, the novel coronavirus was and still is an unrelenting force. According to the time of writing data from Worldometers.info, 4.86 million people succum...
News, Short Squeeze, Breakout and More Instantly...
Terms of the settlement include $12,000,000 cash payment to CytoDyn and elimination of $14,000,000 accounts payable liability from the Company’s balance sheet VANCOUVER, Washington, July 09, 2024 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a bio...
VANCOUVER, Washington, June 27, 2024 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications, announced today that its preclinical MASH study with SMC ...
VANCOUVER, Washington, May 28, 2024 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications, announced today that Dr. Jacob P. Lalezari, Chief Executiv...